Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-06-26 @ 5:08 AM
Study NCT ID:
NCT03113760
Status:
COMPLETED
Last Update Posted:
2025-07-02
First Post:
2017-02-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
Sponsor:
AB2 Bio Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-07-21
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-11-02
Completion Date Type:
ACTUAL
First Submit Date:
2017-02-28
First Submit QC Date:
None
Study First Post Date:
2017-04-14
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-04-02
Results First Submit QC Date:
None
Results First Post Date:
2025-07-02
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-13
Last Update Post Date:
2025-07-02
Last Update Post Date Type:
ACTUAL